CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVEO Pharmaceuticals, Inc., a biotechnology company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced that it will present a total of six oral and poster presentations at the American Association for Cancer Research (AACR) annual meeting, April 12-16, 2008, in San Diego, California. Researchers will present complete results from a Phase 1 trial evaluating AVEO’s triple VEGF receptor inhibitor AV-951 in patients with advanced solid tumors. In addition, findings from preclinical studies utilizing AVEO’s Human Response Platform (HRP™) to evaluate potential biomarkers for AV-951 sensitivity and resistance in proprietary models of breast cancer and other solid tumors will also be presented.
